The effects of anastrozole on neonatal rat skin

Background: Anastrozole is a third-generation nonsteroidal aromatase inhibitor which is used in the treatment of breast cancers. Anastrozole has also been used in the treatment of dermatomyositis skin eruptions but its direct effects on skin have not been well documented. Objective: To study the effects of anastrozole administration on neonatal rat skin. Methods: Forty Sprague-Dawley female newborn rats were separated into two control groups and two experimental groups (n = 10). One day after birth the control group of newborn rats were given daily 0.02 ml saline subcutaneously for a period of 15 days. The first experimental group of rats were treated with 0.05 mg/100g/day anastrozole subcutaneously for 15 days whereas the second experimental group of rats were given 0.25 mg/100g/day anastrozole subcutaneously for 15 days. Histopathological assessments were made and compared with the control groups. Results: Increased keratinization, strippling, hypertrophic epidermal cells and disorganization of the epidermal cells were observed in the first experimental group. In the second experimental group in addition to these pathologic findings acantholysis was observed. Conclusion: The administration of anastrazole in newborn rats showed considerable harmful effects.

Anastrazole; Rat; Skin

[1] Inaloz H.S.,D eveci E.,I naloz S.S.,U na] B.,E ralp A.,C an I.: "The effects of tamoxifen on rat skin". Eur. J. Gynaecol. Oneal., 2002, 23, 50.

[2] Dowsett M., Folkerd E., Doody D., Haynes B.:'The biology of steroid hormones and endocrine treatment of breast cancer". Breast., 2005, 14, 452.

[3] Mouridsen H.T.: "Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women". Curr. Med. Res. Opin. 2006, 22, 1609.

[4] Jonat W.，Hilpert F., Kaufmann M.: "Aromatase inhibitors: a safety comparison". Expert Opin Drug Saf, 2007, 6, 165.

[5] Sereda D., Werth V.P.: "Improvement in dermatomyositis rash associated with the use of antiestrogen medication". Arch. Dermatol,. 2006, 142, 70.

[6] Brueggemeier R.W., Hackett J.C., Diaz-Cruz E.S.: "Aromatase inhibitors in the treatment of breast cancer". Endocr. Rev., 2005, 26, 331.

[7] Simpson E.R.,M ahendroo M.S.,M eans G.D.,K ilgore M.W.,H inshelwood M.M., Graha m-Lorence S. et al.: "Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis". Endocr. Rev. 1994, 15, 342.

[8] Geisler J., King N., Dowsett M., Ottestad L., Lundgren S., Walton P. et al.: "Influence of anastrozole (Arirnidex), a selective, nonsteroidal arornatase inhibitor,on in vivo arornatization and plasma oestrogen levels in postrnenopausal women with breast cancer". Br. J. Cancer, 1996, 74, 1286.

[9] Buzdar A., Jonat W., Howell A., Jones S.E., Blornqvist C., Vogel C.L. et al.: "Anastrozole, a potent and selective aromatase inhibitor,versus megestrol acetate in postrnenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group". J. Clin. Oneal., 1996, 14, 2000.

[10] Bonneterre J., Buzdar A., Nabholtz J.M., Robertson J.F., Thurlimann B., von Euler M. et al.: "Anastrozole is superior to tarnoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma". Cancer, 2001, 92, 2247.

[11] Dewhurst L.O., Gee J.W., Rennie LG., MacNeil S.: "Tarnoxifen, 17 beta-oestradiol and the calmodulin antagonist J8 inhibit human melanoma cell invasion through fibronectin". Br. J. Cancer, 1997, 75, 860.

[12] Bezwoda W.R.: "The treatment of disseminated malignant melanoma with special reference to the role of interferons, vinca alkaloids and tamoxifen". Cancer Treat. Rev., 1997, 23, 17.

[13] Moghadam B.K., Hersini S., Barker B.F.: "Autoimmune progesterone dermatitis and stomatitis". Oral Surg. Oral Med. Oral Pathol. Oral Radial. Endod., 1998, 85, 537.

[14] Tonelli F., Valanzano R., Brandi M.L.: "Pharmacologic treatment of desmoid tumors in familial adenomatous polyposis: results of an in vitro study". Surgery, 1994, 115,473.

[15] Hu D., Hughes M.A., Cherry G.W.: "Topical tamoxifen - a potential therapeutic regime in treating excessive dermal scarring?". Br. J. Plast. Surg., 1998, 51, 462.

[16] Venturini M, Del Mastro L.: " Safety of adjuvant aromatase inhibitor therapy". Cancer Treat Rev., 2006, 32, 548.

[17] Mouridsen H.T.: "Incidence and management of side effects associated with aromatase inhibitorsin the adjuvant treatment of breast cancer in postmenopausal women". Curr. Med. Res. Opin., 2006, 22, 1609.

[18] Mackey J., Gelmon K.: "Adjuvant aromatase inhibitors in breast cancer therapy: significance of musculoskeletal complications". Curr. Opin. Oneal., 2007, 19 (suppl.), S9.

[19] Shoda H.,l nokuma S.,Y ajima N.,Ta naka Y.,S etoguchi K.: "Cutaneous vasculitis developed in a patient with breast cancer undergoing aromatase inhibitor treatment". Ann. Rheum. Dis. 2005, 64, 651.

[20] Conti-Beltraminelli M., Pagani 0., Ballerini G., Richetti A., Graffeo R., Ruggeri M. et al.: "Henoch-Schonlein purpura (HSP) during treatment with anastrozole". Ann. Oneal., 2007, 18, 205.

[21] Xiao X., Hong L., Sheng M.: "Promoting effect of estrogen on the proliferation of hemangioma vascular endothelial cells in vitro". J. Pediatr. Surg., 1999, 34, 1603.

[22] Gagliardi A.R, Hennig B., Collins D.C.: "Antiestrogens inhibit endothelial cell growth stimulated by angiogenic growth factors" Anticancer Res., 1996, 16 (3A), 1101.